CSL Limited (OTCMKTS:CSLLY) Short Interest Update

CSL Limited (OTCMKTS:CSLLY) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 6,300 shares, a decline of 72.0% from the January 15th total of 22,500 shares. Based on an average daily trading volume, of 163,300 shares, the short-interest ratio is presently 0.0 days.

CSL Stock Down 0.5 %

CSL stock traded down $0.42 during midday trading on Wednesday, reaching $80.54. The stock had a trading volume of 63,270 shares, compared to its average volume of 79,794. The company has a fifty day moving average of $87.18 and a 200 day moving average of $94.38. CSL has a 52-week low of $77.37 and a 52-week high of $109.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised shares of CSL to a “strong-buy” rating in a report on Thursday, January 16th.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.